Choosing a target for targeted radionuclide therapy using biomarkers to personalize treatment


Dr. Eckelman comments on targeted radionuclide therapy and its potential role in nuclear medicine drawing a parallel to [131I]iodide in treatment of thyroid abnormalities. A paradigm shift from predominately technical advances requires radioligands designed to have a significant impact on the present standard of care. This shift is especially challenging in diagnosis or staging in neurology, psychiatry, and cardiology and not without challenges in oncology and infectious diseases. A validated single scan approach for diagnostics is also critical to the success of Nuclear Medicine. Choosing a high affinity target for radionuclide therapy that is highly expressed through the disease stages is likewise a challenge.  In this paradigm shift, investigators need a clear understanding of whether the goal is monitoring the change in target as a function of disease and treatment or if the goal is to detect as many abnormalities as possible as a function of disease or treatment. With these goals in mind, choosing a target for radionuclide therapy using biomarkers/diagnostics to personalize treatment has the potential to increase the impact of targeted Nuclear Medicine.

Keywords: radionuclide therapy; phenotype screening; molecular target screening; biomarkers

Citation: Eckelman WC. Choosing a target for targeted radionuclide therapy using biomarkers to personalize treatment. Journal of Diagnostic Imaging in Therapy. 2014; 1(1): 103-109.

Crossref logo


Copyright: © 2014 Eckelman WC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are cited.

Received: 04 November 2014 | Revised: 06 November 2014 | Accepted: 10 November 2014

Published Online 10 November 2014

Click to download PDF